跳至主要内容
临床试验/NCT05307627
NCT05307627撤回不适用

The Effects of Low Dose Naltrexone (LDN) on Diseases of Aging - A Retrospective Cross-sectional Study Into Off-label Use of LDN

AgelessRx1 个研究点 分布在 1 个国家开始时间: 2022年3月14日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
撤回
发起方
试验地点
1
主要终点
Quality of life score

研究概览

简要总结

This retrospective, observational study will assess the health status of short- and long-term low-dose naltrexone (LDN) users.

详细描述

Long-term (>5 years), intermediate-term (1-5 years), and short-term low-dose naltrexone (LDN) users (<12 months) will be contacted for a retrospective, observational assessment of their health status. Participants will be asked to complete a series of questionnaires assessing their quality of life, general physical and mental health, family history, the occurrence of age-related diseases, and immune status. Additionally, blood tests for immune and longevity markers will be optional for a subset of participants.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 120 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults (aged 18-120)
  • Any ethnicity
  • Taking LDN
  • Willing to complete health questionnaires
  • Technologically competent to complete web forms
  • Subgroup: willing to undergo blood testing

排除标准

  • LDN doses over 20 mg/day
  • Terminal cancer patients (defined as stage IV and/or with a life expectancy of 12 months or less)

研究组 & 干预措施

Long-term (>5 years) LDN users

Participants who have been using LDN for over 5 years

干预措施: low-dose naltrexone (Drug)

intermediate-term (1-5 years) LDN users

Participants who have been using LDN for at least 1 year, but shorter than 5 years.

干预措施: low-dose naltrexone (Drug)

short-term (<12 months) LDN users

Participants who have been using LDN for less than a year. This group will serve as the control group.

干预措施: low-dose naltrexone (Drug)

结局指标

主要结局

Quality of life score

时间窗: At enrollment

The short-form (SF)-36 Questionnaire generates scores in the categories: physical function, role limitations due to physical health, role limitations due to emotional problems, energy/fatigue, emotional well-being, social functioning, pain, and general health. Scores up to maximum 100, with higher scores representing better quality of life

Immune Status

时间窗: At enrollment

Immune Status Questionnaire (ISQ) to define a measure of perceived immune status, consists of seven representative immune-associated symptoms and diseases. The Immune Status Questionnaire scores respondents out of 10, with 10 being a better outcome and lower scores worse outcome.

次要结局

  • CMV IgG(At enrollment)
  • General health and family history(At enrollment)
  • Levine's phenotypic age(At enrollment)
  • CD4/CD8 ratio(At enrollment)
  • hsCRP(At enrollment)
  • IL-6(At enrollment)
  • TNFɑ(At enrollment)
  • Methylation age clock testing(At enrollment)

研究者

发起方
AgelessRx
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验